Clinical Trials
49 trialsNCT05800587 2026-05-22
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting
NCT06503146 2026-05-19
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07155174 2026-05-18
SEZanne
AbbVie
Phase 2 Recruiting
NCT07057791 2026-05-14
PrE0510
PrECOG, LLC.
Phase 2 Recruiting
NCT07583511 2026-05-13
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
Sun Yat-sen University
Phase 2 Recruiting
NCT05363280 2026-05-08
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Advenchen Laboratories, LLC
Phase 2 Recruiting
NCT07296809 2026-05-08
SKB500 Combinations in Patients With Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT05957510 2026-05-06
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Guangdong Association of Clinical Trials
Phase 2 Recruiting
NCT07242547 2026-05-05
MERLIN
Fundación GECP
Phase 2 Recruiting
NCT05903092 2026-04-29
MOZART
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05882058 2026-04-27
DAREONâ„¢-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Boehringer Ingelheim
Phase 2 Recruiting
NCT06536868 2026-04-24
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
Second Hospital of Shanxi Medical University
Phase 2 Recruiting
NCT07339059 2026-04-23
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Henry Ford Health System
Phase 2 Recruiting
NCT07476287 2026-04-20
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Pfizer
Phase 2 Recruiting
NCT04919382 2026-04-08
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT05578326 2026-03-30
Study of Trilaciclib and Lurbinectidin
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06424067 2026-03-30
Phase 2 Study of Fingolimod in Lung Cancers
Medical University of South Carolina
Phase 2 Recruiting
NCT06769126 2026-03-30
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
SWOG Cancer Research Network
Phase 2 Recruiting
NCT07055581 2026-03-27
Durvalumab as Consolidation for Patients LS-SCLC
Tongji Hospital
Phase 2 Recruiting
NCT06228066 2026-03-23
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05068232 2026-03-04
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
University of Chicago
Phase 2 Recruiting
NCT06719700 2026-03-03
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT06830694 2026-02-23
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
Samsung Medical Center
Phase 2 Recruiting
NCT07423585 2026-02-20
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT06095505 2026-02-17
ALISCA-Lung1
Puma Biotechnology, Inc.
Phase 2 Recruiting
NCT07149363 2026-02-17
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Alliance Foundation Trials, LLC.
Phase 2 Recruiting
NCT05419076 2026-02-11
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07373964 2026-01-28
A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
China Medical University, China
Phase 2 Recruiting
NCT05450965 2025-12-17
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
University of Maryland, Baltimore
Phase 2 Recruiting
NCT06758700 2025-12-05
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT07245446 2025-11-24
A Study of Ivonescimab in First-Line ES-SCLC
Akeso
Phase 2 Recruiting
NCT05588388 2025-11-17
BELIEVE
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT05924841 2025-09-26
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06838208 2025-09-24
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Anhui Provincial Cancer Hospital
Phase 2 Recruiting
NCT04952480 2025-06-12
DARTS
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT06437509 2025-05-07
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06663098 2025-03-13
CARRY-ON
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Recruiting
NCT06771518 2025-01-13
Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
Regina Elena Cancer Institute
Phase 2 Recruiting
NCT06769971 2025-01-10
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Sichuan University
Phase 2 Recruiting
NCT06749691 2024-12-27
LIAES
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06698965 2024-11-21
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Shanghai Chest Hospital
Phase 2 Recruiting
NCT04951947 2024-09-19
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT06562920 2024-08-20
Neoadjuvant
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT06295926 2024-07-22
Serplulimab Combined With CCRT for LS-SCLC.
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT06485544 2024-07-03
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
Tang-Du Hospital
Phase 2 Recruiting
NCT06256237 2024-05-29
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT06223711 2024-04-05
Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
Universität des Saarlandes
Phase 2 Recruiting
NCT06177925 2023-12-20
A Phase â…¡ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT04539977 2023-05-09
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting